目的： 建立首批1,6-脱水衍生物系统适用性对照品，完善国家标准。方法：以欧洲药典依诺肝素钠对照品(EP Enoxaparin Sodium，Batch5)为系统适用性对照品，采用依诺肝素钠新国家标准草案 “1,6-脱水衍生物”检查法，对依诺肝素钠国家对照品(批号：140810-201801)进行1,6-脱水衍生物含量测定，由全国14个药品检验机构及依诺肝素生产企业实验室协作标定。结果：对依诺肝素钠系统适用性国家对照品(批号：140810-201801)1,6-脱水衍生物含量标定结果为20.3%，并对实验室内误差进行考察，14个实验室中有1个实验室(Lab1)标准差(SD)为1.8%，5个实验室(Lab2、Lab4、Lab10、 Lab11和Lab13)的SD为0.5%~0.7%，其余8个实验室的SD值均小于0.5%。对实验室间误差进行考察，有效数据的SD值为0.6%，相对标准偏差(RSD)为3.2%。结论：经国家药品标准物质委员会审定后批准， 依诺肝素系统适用性国家对照品(批号：140810-201801)增加1,6-脱水衍生物含量赋值，可以用于依诺肝素钠1,6-脱水衍生物检查系统适用性考察使用。
Objective: The new draft of National standard for enoxaparin sodium has added the determination item of 1,6-anhydro derivatives. The 1st batch of 1,6-anhydro derivatives of national reference standard should be established for systematic applicability. Methods: The European Pharmacopoeia enoxaparin sodium reference substance (EP enoxaparin sodium, batch 5) was used as the system applicability reference substance. The national standard (batch number: 140810-201801) of enoxaparin was used to determine the content of 1,6-anhydro derivatives by the new national standard draft "1, 6-dehydrated derivatives" examination method, which was determined by 14 national drug inspection institutions and laboratories of enoxaparin manufacturers. Results: The content calibration result of 1,6-anhydroderivatives was 20.3% in the national standard (batch number: 140810-201801) applicable to enoxaparin sodium system, and the laboratory errors were investigated. Among the 14 laboratories, the standard deviation (SD) of 1 laboratory (Lab1) was 1.8%, the SD of 5 laboratories (Lab2, Lab4, Lab10, Lab11 and Lab13) was 0.5%-0.7%, and the SD values of the remaining 8 laboratories were all less than 0.50%. When the interlaboratory errors were examined, the SD of the valid data was 0.6%, and the relative standard deviation (RSD) was 3.2%. Conclusion: After approval by National Drug Standard Substances Committee, the national standard applicable to enoxaparin sodium (batch number: 140810-201801) was approved to add the content assignment value of 1,6-anhydro derivatives. This national standard could be used in the test of enoxaparin 1,6-dehydrated derivatives in enoxaparin sodium Chinese national standard.
[1] Zhang C,Tang F,Zhang J,et al.Uncovering the Detailed Mode of Cleavage of Heparinase I Toward Structurally Defined Heparin Oligosaccharides[J].Int J Biol Macromol.2019 Dec 1;141:756-764.DOI:10.1016/j.ijbiomac.2019.08.260.Epub 2019 Aug 31.PMID:31479666.
[2] Xu X,Li D,Chi L,et al.Fragment Profiling of Low Molecular Weight Heparins Using Reversed Phase Ion Pair Liquid Chromatography-electrospray Mass Spectrometry[J].Carbohydr Res，2015，407：26-33.
[3] 王悦，李京，李颖颖，等.高效阴离子交换色谱法测定依诺肝素钠1,6-脱水衍生物含量[J].中国药学杂志，2014，49（16）：1461-1466.
[4] Giuseppe Mascellani,Marco Guerrini,Giangiacomo Torri,et al.Characterization of di-and Monosulfated,Unsaturated Heparin Disaccharides with Terminal N-sulfated 1,6-anhydro-β-D-mannosamine residues[J].Carbohydr Res，2007，342（6）：835-842.
[5] Rahul G Ingle,Aayush S Agarwal.A World of Low Molecular Weight Heparins(LMWHs)Enoxaparin as a Promising Moiety-A review[J].Carbohydr Polym，2014，106：148-153.
[6] Marco Guerrini,Stefano Elli,Davide Gaudesi,et al.Effects on Molecular Conformation and Anticoagulant Activities of 1,6-Anhydrosugars at the Reducing Terminal of Antithrombin-binding Octasaccharides Isolated from Lowmolecular-weight Heparin Enoxaparin[J].J.Med.Chem，2010，53：8030-8040.
[7] 祝贺，吕友晶，韩现伟，等.不同1,6-酐衍生度依诺肝素钠结构及其抗凝血活性比较[J].药学学报，2014，49（7）：1049-53.
[8] 张筱红，任连杰，余立，等.依诺肝素钠的质量控制思路[J].中国新药杂志，2012，21（11）：1200-1202.
[9] USP42-NF37[S].2019：6531-6537.
[10] EP10.0[S].2020：2502-2504.
[11] 李京，王悦，宋玉娟，等.首批低分子肝素相对分子质量国家对照品的建立[J].中国药学杂志，2020，55（10）：824-837.
[12] Chen L,Ouyang Y,Yan N,et al.Comprehensive Analysis of Heparinase Derived Heparin-products Using Twodimensional Liquid Chromatography Coupled with Mass Spectrometry[J].J Chromatorg A，2021，643：462049.
[13] Bhushan I,Alabbas A,Sistla JC,et al.Heparin Depolymerization by Immobilized Heparinase:A Review[J].Int J Biol Macromol，2017，99：721-730.
[14] Wu J,Zhang C,Mei X,et al.Controllable Production of Low Molecular Weight Heparins by Combinations of Heparinase I/II/III[J].Carbohydr Polym，2014，101：484-492.DOI:10.1016/j.carbpol.2013.09.052.Epub 2013 Sep 23.PMID:24299802.
[15] 朱梦，李笃信，杨凯歌，等.不同来源肝素酶I对依诺肝素钠降解作用的研究[J].药物分析杂志，2020，40（7）：1254-1261.
